Du är här

2014-04-24

Bavarian Nordic A/S: Bavarian Nordic Welcomes Gerard van Odijk as New Chairman of the Board

KVISTGAARD, Denmark, April 24, 2014
- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today, that following
the ordinary general meeting, the board has elected Gerard van Odijk, M.D. as
new chairman of the board of Bavarian Nordic. He succeeds Asger Aamund who
has served as chairman since 1994. Furthermore Anders Gersel Pedersen, M.D.
has been elected deputy chairman of the board.

Dr. van Odijk has served as board member in Bavarian Nordic since 2008. He is
an independent advisor for the pharmaceutical industry in which he has
long-time experience from various executive positions. He retired as
president and CEO of Teva Pharmaceuticals Europe B.V. in 2012 and has
previously held various senior positions in GlaxoSmithKline (GSK).

Dr. van Odijk is also chairman of the board of Merus Biopharmaceuticals B.V.
and member of the board of UDG Healthcare plc. He is a Dutch national, born
in 1957.

Anders Gersel Pedersen, M.D. and deputy chairman has served on the board since
2010. Dr. Pedersen is executive vice president of research and development at
H. Lundbeck A/S. He is deputy chairman of the board of Genmab A/S and a
member of the board of directors of ALK-Abelló A/S. Dr. Pedersen is a Danish
national, born in 1951.

Anders Hedegaard, President&CEO of Bavarian Nordic said: "After having served
on the board for more than five years, we are happy to welcome Gerard as new
chairman of the board. His inside knowledge from our company combined with
his extensive executive background within publicly traded companies in the
international pharmaceutical industry will contribute to our continued
progress in the coming years."

Anders Hedegaard, President&CEO.

Contacts
Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47
43
Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious
diseases. Lead product candidates are PROSTVAC®, an immunotherapy product
candidate for advanced prostate cancer that is the subject of an ongoing
pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox
vaccine candidate in Phase 3 development, which is being developed and
supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. The vaccine is approved in Canada under
the trade name IMVAMUNE and in the European Union under the trade name
IMVANEX®.

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored
Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visitwww.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control
that could cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking statements
include statements concerning our plans, objectives, goals, future events,
performance and/or other information that is not historical information. We
undertake no obligation to publicly update or revise forward-looking
statements to reflect subsequent events or circumstances after the date made,
except as required by law.

201407uk
http://hugin.info/100065/R/1779857/608330.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire

HUG#1779857

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.